Replies to post #68002 on Biotech Values

[poorgradstudent]

>No—only the US was broken out (26% of total sales).<

Yeah, so my best guess is that Bayer is doing a better job ex-US, especially as they continue to pick off countries one by one for HCC approval. Japan got RCC approval in the first half of this year, and approval in China for HCC was at the end of July. I suspect those are slowly starting to help sales in the face of RCC competition in the US.

[microcapfun]

ONXX

>>No—only the US was broken out (26% of total sales).<<

Onyx also broke out Japan - but only in dollars.

U.S.: $48M
Japan: $12.746M
Worldwide: 121M euros or ~$181.5M

After Japan provides approval and reimbursement in HCC, they may well generate more sales than the U.S., because Japan has ~3 times as many liver cancer cases as the U.S. However Onyx only gets a 7% royalty from Japan.

micro